A large U.S. Department of Veterans Affairs cohort study found that Nicotinamide use was associated with a 14% lower risk of new keratinocyte skin cancers, driven by a 22% reduction in cSCC and no reduction in BCC. The strongest benefit (56% lower risk) appeared when nicotinamide was started after a patient’s first skin cancer, with diminishing returns after multiple cancers.